Transcriptional regulator The basic helix-loop-helix leucinezipper (bHLHZipper) protein family includes c-Myc. The c-MYC protein's target genes are involved in a variety of cellular processes, including the cell cycle, survival, protein synthesis, cell adhesion, and the expression of microRNAs. In addition, c-Myc, one of the four factors required for the induction of pluripotent stem (iPS) cells from somatic cells, is thought to contribute to the maintenance of cancer stem-like cells (CSCs). The majority of c-Myc'sbiologicalactivities necessitate heterodimerization with its activation partner Max.
Additionally, c-Myc is a component of a dynamic network, which interacts selectively with different transcriptional coregulators, histone-modifying enzymes, and members of the network. Tumorigenesis is linked to c-MYC expression that is dysregulated as a result of gene amplification, retroviral insertion, or chromosomal translocation. One extremely promising target for cancer treatment is c-Myc.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V1587 | 10058-F4 | 403811-55-2 | 10058-F4 (10058F4; 10058 F4) is a novel potent and selective c-Myc inhibitor with potential antineoplastic activity. |
|
V2724 | 10074-G5 | 413611-93-5 | 10074-G5 is a potent inhibitor of c-Myc-Max dimerization and interaction with an IC50 of 146 μM and with anticancer activities. |
|
V51576 | IRES-C11 | 342416-30-2 | IRES-C11 is a selective translation inhibitor that binds to the c-MYC internal ribosome entry site. |
|
V4012 | ML327 | 1883510-31-3 | ML327 is a novel potent MYC blocker which also de-represses E-cadherin transcription, partially reverses EMT (Epithelial-to-Mesenchymal Transition), and inhibits cancer cell invasiveness and tumor cell migration in vitro and in vivo. |
|
V37599 | MYCi361 (NUCC-0196361) | 2289690-31-7 | MYCi361 (NUCC0196361) is a novel and potent MYC inhibitor (Kd = 3.2 μM) with potential anticancer activity, it demonstrated a narrow therapeutic index. |
|
V37600 | MYCi975 (NUCC-0200975) | 2289691-01-4 | MYCi975 (NUCC-0200975), anMYCi361analog, is a novel, orally bioactive and potent MYC inhibitor (Kd = 3.2 μM) with potential anticancer activity. |
|
V22075 | Mycro3 | 944547-46-0 | Mycro 3 is an orally bioactive, potent and specific inhibitor of Myc-Max dimerization. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
